CLINICAL TRIAL: ALENDRONATE SODIUM IN JUVENILE OSTEOPOROSIS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 青少年骨质疏松症（软骨或脆弱的骨头，可以骨折）发生在男性和女性儿童和青少年。 这是一种罕见的骨骼疾病，发生在青春期之前，原因不明。 治疗的基本原理是防止骨折和骨骼畸形的发生。 20名患有骨质疏松症的儿童将参加这项研究。 在我们早期的研究中，药物福善美被证明对治疗儿童骨质疏松症有效。 本研究旨在进一步确定福善美治疗的安全性和有效性。 FDA认为福善美是本研究期间使用的研究药物。项目持续时间为3年，患者治疗持续时间为2年，包括24个月的治疗期和24个月的未治疗期。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Juvenile Osteoporosis (soft or weak bones that can fracture) occurs in both male and female children and adolescents. It is an uncommon bone disease that occurs just before puberty and the cause is unknown. The rationale for the treatment is to prevent the occurrence of fractures and skeletal deformities. Twenty children with osteoporosis will participate in the study. The drug Fosamax was shown to be effective for the treatment of osteoporosis in children in our earlier study. This study is designed to determine further the safety and efficacy of Fosamax therapy. Fosamax is considered an investigational drug by the FDA for its use during this study. The duration of the project is 3 years and the duration of the patient treatment is 2 years involving 24 months treatment period and 24 months untreated period.